The Journal of Pediatrics
Volume 147, Issue 1 , Pages 3-4 , July 2005

Many Faces of Portopulmonary Hypertension

  • Michael J. Krowka, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Michael J. Krowka, MD, 200 1st Street SW, Rochester, MN 55905.

References 

  1. Blendis L, Wong F. Portopulmonary hypertension: an increasingly important complication of cirrhosis. Gastroenterology. 2003;126:622–624
  2. Condino AA, O'Connor JA, Narkawicz MR, Mengshol S, Whitworth JR, Claussen L, et al. Portopulmonary hypertension in pediatric patients. J Pedriatr. 2005;147:20–26
  3. Krowka MJ, Plevak DJ, Findlay JF, Rosen CB, Wiesner RH, Krom RAF. Pulmonary hemodynamics and perioperative cardiopulmonary related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6:443–450
  4. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RF, et al. Accuracy of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453–458
  5. Krowka MJ, Frantz RF, McGoon MD, Wiesner RH. Improvement if pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641–648
  6. Minder S, Fischier M, Muelhaupt B, Zalunardo MO, Jenni R, Clavien PA, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J. 2004;24:703–707
  7. Sulica E, Emre S, Poon M. Medical management of portopulmonary hypertension and right heart failure prior to living-related liver transplantation. CHF. 2004;10:192–194
  8. Halank M, Marx C, Miehlke S, Hoeftken G. Use of inhaled iloprost in the treatment of portopulmonary hypertension. J of Gastroenterology. 2004;39:1222–1223
  9. Molnar C, Alber H, Cooleselli D, Vogel W, Kahler CM. Successful switch from inhalitive iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klinis Woch. 2004;116:627–630
  10. Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation. 2004;77:1775–1776
  11. Hinterhuber L, Graziaedi IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol. 2004;2:1039–1042
  12. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?. Gastroenterology. 2005;128:64–68
  13. Hoeper MM, Halank M, Hoeffken G, Seyfarth HJ, Schauer J, Niedermer J, et al. Bosentan for the treatment of portopulmonary hypertension. Eur Respir J. 2005;25:502–508
  14. Clift PF, Bramhall S, Isaac JL. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation. 2004;77:1774–1776
  15. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl. 2004;10:945–950
  16. Krowka MJ, Mandell SM, Ramsay MAE, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10:174–182
  17. Shah T, Isaac J, Adams D, Kelly D, the Liver Units . Development of hepatopulmonary syndrome and portopulmonary hypertension in a paediatric liver transplant patient. Pediatr Transpl. 2005;9:127–131

PII: S0022-3476(05)00321-5

doi: 10.1016/j.jpeds.2005.04.014

The Journal of Pediatrics
Volume 147, Issue 1 , Pages 3-4 , July 2005

Article Tools